Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The risk of adrenal insufficiency in patients with nonclassical congenital adrenal hyperplasia due to 21-hydroxylase deficiency is not well documented. Indication of cortisol replacement therapy in situation of acute stress or at long term is thus controversial. The mineralocorticoid reserve of these patients has never been evaluated.
Hypothesis: The glucocorticoid and mineralocorticoid function of the adrenal glands in women with nonclassical 21-hydroxylase deficiency is comparable with the adrenal functions of healthy age- sexe- and BMI-matched subjects.
The primary end-point of the study is to evaluate the glucocorticoid function of the adrenal glands in women with nonclassical 21-hydroxylase deficiency (= patients) by comparing the maximal cortisol concentrations obtained during insulin tolerance test (ITT) in the patients and in the healthy volunteers.
The secondary end-point of the study is to determine the % of patients with a maximal plasma cortisol concentration greater or equal to 18μg/dL during ITT; compare the maximal plasma ACTH and salivary cortisol concentration during ITT in the two study groups; to evaluate the mineralocorticoid function of the patients by comparing the variations (changes from baseline) of the plasma renin, aldosterone, urinary aldosterone, systolic and diastolic blood pressure and pulse wave velocity in response to sodium depletion in the patients and in the healthy volunteers.
Women with nonclassical 21-hydroxylase deficiency followed in the Endocrinology and reproduction illnesses Service of the BICETRE Hospital, LE KREMLIN-BICETRE, France and female healthy volunteers will be proposed to participate.
Before inclusion patients must be genotyped and both patients and healthy volunteers must undergo an ACTH (Synacthen 250 μg IV) test for plasma cortisol and 17-hydroxyprogesterone concentration assessments.
After inclusion:
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Cases | Experimental | Functional explorations of cortisol and aldosterone production during stimulation by ITT and sodium depletion respectively in female patients with non classical 21-hydroxylase deficiency. |
|
| Control | Experimental | Functional explorations of cortisol and aldosterone production during stimulation by ITT and sodium depletion respectively in healthy female controls. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Functional explorations | Other | Functional explorations of cortisol and aldosterone production during stimulation by ITT and sodium depletion respectively |
|
| Measure | Description | Time Frame |
|---|---|---|
| Maximal plasma cortisol concentration | Repeated measures 15, 30, 45, 60, 90 and 120 minutes after insulin IV injection | Before and up to two hours after Insulin injection (Insulin tolerance test) |
| Measure | Description | Time Frame |
|---|---|---|
| % of patients with maximal plasma cortisol concentration >=18microg/dl | Repeated measures 15, 30, 45, 60, 90 and 120 minutes after insulin IV injection | Before and up to two hours after Insulin injection (Insulin tolerance test) |
| Maximal plasma ACTH concentration |
Not provided
Inclusion Criteria:
Groupe of patients:
Groupe of healthy volunteers :
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Peter Kamenicky, MD, PhD | Assistance Publique Hôpitaux de Paris - Bicêtre Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Assistance Publique - Hôpitaux de Paris, Bicêtre Hospital | Le Kremlin-Bicêtre | 94 275 | France |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 31529070 | Derived | Kamenicky P, Blanchard A, Lamaziere A, Piedvache C, Donadille B, Duranteau L, Bry H, Gautier JF, Salenave S, Raffin-Sanson ML, Genc S, Pietri L, Christin-Maitre S, Thomas J, Lorthioir A, Azizi M, Chanson P, Le Bouc Y, Brailly-Tabard S, Young J. Cortisol and Aldosterone Responses to Hypoglycemia and Na Depletion in Women With Non-Classic 21-Hydroxylase Deficiency. J Clin Endocrinol Metab. 2020 Jan 1;105(1):dgz005. doi: 10.1210/clinem/dgz005. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000312 | Adrenal Hyperplasia, Congenital |
| C535979 | Congenital adrenal hyperplasia due to 21 hydroxylase deficiency |
| ID | Term |
|---|---|
| D047808 | Adrenogenital Syndrome |
| D012734 | Disorders of Sex Development |
| D014564 | Urogenital Abnormalities |
| D052776 | Female Urogenital Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Functional explorations | Other | Functional explorations of cortisol and aldosterone production during stimulation by ITT and sodium depletion respectively |
|
Repeated measures 15, 30, 45, 60, 90 and 120 minutes after insulin IV injection |
| Before and up to two hours after Insulin injection (Insulin tolerance test) |
| Maximal salivary cortisol concentration | Repeated measures 15, 30, 45, 60, 90 and 120 minutes after insulin IV injection | Before and up to two hours after Insulin injection (Insulin tolerance test) |
| Variation (change from baseline) of plasma rennin and plasma aldosterone concentration | Repeated measures 1, 2, 3, 6, 9, 12, 24 hours after oral furosemide administration | Before and up to 24 hours after oral furosemide administration (Sodium depletion test) |
| Variation (change from baseline) of urinary aldosterone concentration | Repeated measures in 4-hour urine portions after oral furosemide administration | Before and up to 24 hours after oral furosemide administration (Sodium depletion test) |
| Variation (change from baseline) of the systolic, diastolic blood pressure and pulse wave velocity | Repeated measures 1, 2, 3, 6, 9, 12, 24 hours after oral furosemide administration | Before and up to 24 hours after oral furosemide administration (Sodium depletion test) |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D052801 | Male Urogenital Diseases |
| D000013 | Congenital Abnormalities |
| D009358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |
| D030342 | Genetic Diseases, Inborn |
| D043202 | Steroid Metabolism, Inborn Errors |
| D008661 | Metabolism, Inborn Errors |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
| D000307 | Adrenal Gland Diseases |
| D004700 | Endocrine System Diseases |
| D006058 | Gonadal Disorders |